StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Question

<< Previous

Bullboard Posts

Next >>

Comment by molotov420on Mar 22, 2022 11:02am

91 Views

Post# 34534385

RE:RE:Question

haha, better start chewing now. Dont think they are ever going to spell out "Aristotle Revenue" for you. Lab Revenue is likely as clear as it will get.

The 400K is shown on the last financial statement page 28/29. Clinical consultation is HC. They show 273K+115K deferred. Pretty close to 400K in the month of Sept.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1